Status:
COMPLETED
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors
Lead Sponsor:
Genentech, Inc.
Conditions:
Solid Cancers
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standa...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior regimen
- Evaluable or measurable disease per RECIST (in certain circumstances, prostate or ovarian cancer patients with non-measurable disease)
Exclusion
- Inadequate hematologic or organ function
- Anti-cancer therapy within 4 weeks prior to initiation of study treatment
- Recent history of or current clinically significant gastrointestinal, cardiovascular or pulmonary disorders
- Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytics, or a filter of the inferior vena cava
- Active infection or autoimmune disease
- Known human immunodeficiency virus (HIV) infection
- Pregnancy or breast feeding
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00747734
Start Date
September 1 2008
Last Update
April 20 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.